Publications by authors named "Thomas Emm"

Claim this Profile
T
The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers.
Jack G Shi, Xuejun Chen, Fiona Lee, Thomas Emm, Peggy A Scherle

J Clin Pharmacol· December 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients.
Xuejun Chen, Jack G Shi, Thomas Emm, Peggy A Scherle, Ryan F McGee

Clin Pharmacol Drug Dev· January 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
Jack G Shi, Xuejun Chen, Thomas Emm, Peggy A Scherle, Ryan F McGee

J Clin Pharmacol· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The pharmacokinetics, pharmacodynamics, and safety of orally dosed INCB018424 phosphate in healthy volunteers.
Jack G Shi, Xuejun Chen, Ryan F McGee, Robert R Landman, Thomas Emm

J Clin Pharmacol· December 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Simultaneous determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by LC-MS/MS using supported liquid extraction.
Yu Li, Thomas Emm, Swamy Yeleswaram

Biomed Chromatogr· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metabolism, excretion, and pharmacokinetics of [14C]INCB018424, a selective Janus tyrosine kinase 1/2 inhibitor, in humans.
Adam D Shilling, Frank M Nedza, Thomas Emm, Sharon Diamond, Edward McKeever

Drug Metab Dispos· November 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Potent benzimidazole sulfonamide protein tyrosine phosphatase 1B inhibitors containing the heterocyclic (S)-isothiazolidinone phosphotyrosine mimetic.
Andrew P Combs, Wenyu Zhu, Matthew L Crawley, Brian Glass, Padmaja Polam, Thomas Emm

J Med Chem· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis